Mochida Pharmaceutical’s Aloxi: Antiemetic option for chemotherapy patients

Responsible: ad hoc news Lifestyle & Consumer Desk. Reviewed prior to publication on June 12, 2026 at 11:38:08 AM ET. Details in the imprint.

Aloxi is one of Mochida Pharmaceutical’s key prescription brands in supportive oncology care, helping patients on moderately and highly emetogenic chemotherapy regimens manage nausea and vomiting. The drug, which contains the active ingredient palonosetron hydrochloride, is a selective 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in adults and pediatric patients. In Japan, Aloxi has secured indications both as a single agent and in combination antiemetic regimens, positioning it as a clinically important option in hospitals and cancer centers. For U.S. readers, Aloxi is more broadly known via license partners, but it remains a recognizable brand name in global oncology practice.

How Aloxi works and where it fits in cancer care

Palonosetron, the active substance in Aloxi, belongs to the class of serotonin (5-HT3) receptor antagonists that block serotonin activity centrally and peripherally, which is a key pathway involved in triggering nausea and vomiting after chemotherapy. Unlike some older 5-HT3 antagonists, palonosetron shows a relatively long plasma half-life of around 40 hours, which supports its use for both acute (within 24 hours) and delayed (24 to 120 hours) phases of CINV with a single dose in many regimens. Clinical studies referenced in regulatory documents report that palonosetron-based regimens can help reduce the incidence of vomiting and the need for rescue antiemetic medication when used appropriately. This pharmacologic profile has contributed to its inclusion in antiemetic guidelines and routine protocols in oncology departments.

Aloxi is typically given intravenously as a part of pre-chemotherapy preparation, with dose and timing defined by regimen and patient age. In adult patients receiving moderately emetogenic chemotherapy, a single 0.25 mg IV dose of palonosetron administered about 30 minutes before chemotherapy has been widely adopted. For highly emetogenic regimens, palonosetron is often used in a three-drug combination that pairs a 5-HT3 receptor antagonist with a neurokinin-1 (NK1) receptor antagonist and dexamethasone, following international antiemetic guideline recommendations. Mochida’s Japanese labeling reflects these evidence-based patterns and clarifies that the drug is intended for use under physician supervision in a hospital or clinical setting. Patients in the United States likewise receive palonosetron in infusion centers and oncology clinics, generally covered under medical benefits rather than pharmacy benefits because it is administered by health professionals.

In Japan, Aloxi has been available for more than a decade and has become part of Mochida Pharmaceutical’s established product portfolio in the oncology-supportive-care segment. The company’s English-language materials highlight Aloxi as a contributor to revenue in its ethical pharmaceuticals business, alongside cardiovascular and central nervous system products. While Mochida does not break out Aloxi sales separately in all investor documents, its positioning as a long-standing antiemetic brand aimed at hospital prescribing provides a relatively stable demand base tied to oncology procedure volumes. Internationally, palonosetron-based products are marketed under Aloxi and related brand names by license partners; these alliances extend the reach of Mochida’s innovation into North America and Europe via co-development and out-licensing agreements. For U.S. consumers and retail investors, Aloxi therefore functions as a window into Mochida’s know-how in niche but clinically critical therapeutic niches such as CINV management.

Safety and tolerability data for palonosetron indicate that the drug is generally well tolerated, with common adverse reactions including headache, constipation, and injection-site reactions, as summarized in U.S. prescribing information and Japanese product documentation. As with other 5-HT3 antagonists, there is attention to potential effects on cardiac repolarization; prescribing information warns about QT prolongation risk and recommends cautious use in patients with known risk factors. Healthcare professionals also monitor for possible hypersensitivity reactions and tailor antiemetic regimens in pregnant or breastfeeding patients according to clinical guidelines. Because Aloxi is administered in controlled environments, oncologists and nurses can respond quickly if any unexpected reactions occur. For patients, the practical takeaway is that Aloxi is not a self-medication product but a physician-directed therapy integrated into chemotherapy planning, often discussed during pre-treatment counseling sessions.

Pricing and reimbursement details for Aloxi vary by market, and list prices in hospital settings are typically not visible to end consumers. In Japan, the product is covered under the national health insurance reimbursement framework; Mochida’s company reports classify Aloxi among reimbursed hospital-use drugs that are subject to periodic price revisions by the authorities. In the United States, purchasers usually encounter palonosetron as part of a bundled infusion service billed to insurers or Medicare/Medicaid, so individual drug pricing line items are rarely presented directly to patients. For individuals comparing antiemetic options, treatment selection is primarily driven by oncologist judgment, guideline recommendations, prior treatment response, and insurance coverage rather than retail-style out-of-pocket pricing. Consumers watching the product market may therefore focus less on sticker prices and more on whether long-established agents like palonosetron continue to be included in evolving antiemetic standards of care, particularly as biosimilars or newer therapeutics emerge.

From a corporate perspective, Aloxi illustrates how Mochida balances specialty therapeutics with broader portfolio needs. The company’s disclosures describe a pipeline and product mix spanning psychiatric, cardiovascular, women’s health, and gastroenterology indications in addition to oncology support. Aloxi’s recurring demand from hospital oncology departments helps underpin this mix with a relatively predictable prescription base, even as Mochida invests in newer candidates. For investors examining Mochida’s equity, Aloxi is one among several branded drugs that support the firm’s prescription drug revenue. Shares of Mochida (JP3778400006, ticker MCHDF) last traded over-the-counter in the U.S. as an unsponsored ADR; the primary listing is on the Tokyo Stock Exchange, and recent price data are quoted in yen on that market.

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.